article thumbnail

Company Offering $10K for a 30 Day Phone Detox, Apply Now

Tech.Co

Siggi’s Dairy Sets Digital Detox Challenge “We're introducing a new kind of “Dry January” this year,” Siggi’s explains in a recent blog post. So, if you think you can last for the whole month without your phone if $10,000 is put on the line, here’s an outline of the competition and how to enter.

Company 228
article thumbnail

Cancer Wrap: Blueprint, Checkmate, More AACR News & Phase 3 Blues

Xconomy

There were results from earlier stages of clinical studies and preclinical research, which is the traditional material for AACR, as well as a couple of late-stage letdowns that came to light. Here’s a sample of other cancer news blowing in the Windy City and beyond this week.

News 65
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More

Xconomy

Making changes in the midst of the study was a no-no. Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. In recent years, regulators have showed openness to clinical trial designs intended to make drug testing more efficient.

News 89
article thumbnail

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

Xconomy

Biogen’s (NASDAQ: BIIB ) earnings call this week was the first since its Alzheimer’s drug aducanumab failed in a Phase 3 study and eviscerated the company’s shares. But it’s earnings season now, so some of them don’t have much choice. CEO Michel Vounatsos acknowledged the drug didn’t work.

News 94
article thumbnail

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

Xconomy

Intercept (NASDAQ: ICPT ) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?

News 86
article thumbnail

Bio Roundup: Amarin’s Stunner, Lung Cancer News, Data Dumps & More

Xconomy

While other groups tested other fish oils and found no evidence of concrete cardiovascular benefits , Amarin pressed on with a massive study, bleeding cash for years. Amarin said this week that the REDUCE-IT study showed Vascepa lowered the risk of heart disease, marking a. The strategy seems to have paid off.

News 73
article thumbnail

BLOGGER ALERT: How to Start a Blog and Make Money Blogging

Tech Zulu Event

In this article you’ll discover how to start a blog that makes money. There are four types of blogs; written blogs, video blogs, photo blogs and a combination of these. We’ll primarily be discussing written blogs. There are two different components to make money blogging. Let’s discuss. Not really.